Zura Bio (NASDAQ:ZURA) Now Covered by Leerink Partners

Leerink Partners initiated coverage on shares of Zura Bio (NASDAQ:ZURA) in a research note issued to investors on Monday morning, MarketBeat reports. The brokerage issued an outperform rating and a $15.00 price objective on the stock.

Several other research firms have also recently commented on ZURA. Piper Sandler restated an “overweight” rating and set a $26.00 price target on shares of Zura Bio in a research note on Thursday, September 19th. HC Wainwright reissued a “neutral” rating and issued a $5.00 price objective on shares of Zura Bio in a research note on Monday, October 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Zura Bio in a research note on Friday, October 18th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Zura Bio currently has an average rating of “Buy” and a consensus price target of $16.75.

Zura Bio Price Performance

Shares of Zura Bio stock opened at $4.47 on Monday. Zura Bio has a 1 year low of $2.00 and a 1 year high of $6.35. The company’s fifty day moving average is $4.17 and its two-hundred day moving average is $4.10.

Zura Bio (NASDAQ:ZURA) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). On average, sell-side analysts anticipate that Zura Bio will post -0.47 earnings per share for the current year.

Insider Activity at Zura Bio

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total value of $200,187.36. Following the completion of the transaction, the director now owns 2,085,418 shares in the company, valued at approximately $8,070,567.66. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 22.10% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in ZURA. Affinity Asset Advisors LLC acquired a new position in Zura Bio during the first quarter worth $1,157,000. Bank of New York Mellon Corp increased its position in shares of Zura Bio by 15.8% in the second quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company’s stock valued at $165,000 after buying an additional 6,412 shares in the last quarter. Renaissance Technologies LLC raised its stake in shares of Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company’s stock worth $61,000 after buying an additional 5,900 shares during the last quarter. Great Point Partners LLC raised its stake in shares of Zura Bio by 68.3% during the 2nd quarter. Great Point Partners LLC now owns 4,642,241 shares of the company’s stock worth $16,248,000 after buying an additional 1,884,501 shares during the last quarter. Finally, Armistice Capital LLC boosted its position in shares of Zura Bio by 53.2% in the 2nd quarter. Armistice Capital LLC now owns 2,524,000 shares of the company’s stock worth $8,834,000 after buying an additional 876,000 shares in the last quarter. 61.14% of the stock is currently owned by institutional investors and hedge funds.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.